To be clear, when you authorize — even unknowingly — third-party websites (sites) and applications (apps) to get […]
Trump administration officials make rules, regulations, and policies that impact most aspects of our lives. Today in government, […]
The Food and Drug Administration (FDA) released a statement today on its plan to assure American’s have access to […]
The Children are our Future The children are our future. Yet American children are being slaughtered, at school. […]
The extent to which 340B covered entities receive duplicate discounts from pharmaceutical manufacturers who take part in the Medicaid Drug Rebate Program (MDRP) is widely documented.
The Medicaid Exclusion File
The Health Resources and Services Administration (HRSA) established the 340B Medicaid Exclusion File (MEF) as The mechanism to aid 340B covered entities and states to prevent duplicate discounts for drugs subject to Medicaid rebates.
But in terms of efficacy, the MEF is insufficient in mitigating duplicate discounts. An estimated $2 billion in improper rebate payments are paid by pharmaceutical manufacturers — and received by 340B covered entities — on an annual basis.
Technological advances have changed the way people work, consume information, and live. Innovations in technology gave impetus to Artificial […]